{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"8.9","upperLimit":"35.9","value":"35.9"},{"comment":"Not reached","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not reached","groupId":"OG003","lowerLimit":"7.8","upperLimit":"NA","value":"20.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Distant progression is defined as the first occurrence of distant metastasis. Distant progression-free survival time is measured from the date of randomization to the date of first distant progression, death, or last known follow-up (censored). Distant progression-free survival rates are estimated using the Kaplan-Meier method. No testing was done due to early study termination.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG000","title":"EGFR: Erlotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG001","title":"EGFR: No Erlotinib"},{"description":"Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG002","title":"ALK: Crizotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG003","title":"ALK: No Crizotinib"}],"paramType":"MEDIAN","populationDescription":"Eligible patients","reportingStatus":"POSTED","timeFrame":"From randomization to study termination. Maximum follow-up was 39.0 months","title":"Distant Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}